Breast Cancer Research and Treatment

, Volume 29, Issue 3, pp 265–270 | Cite as

Lack of prognostic value of epidermal growth factor receptor in a series of 229 T1/T2, N0/N1 breast cancers, with well defined prognostic parameters

  • M. Bolla
  • M. Chedin
  • M. Colonna
  • J. Marron-Charrière
  • B. Rostaing-Puissant
  • D. Pasquier
  • M. H. Panh
  • P. Winckel
  • E. M. Chambaz
Report

Summary

The prognostic value of epidermal growth factor receptor (EGF-R) was prospectively assessed in a series of 229 clinical T1-T2, N0-N1 breast carcinomas diagnosed between May 1987 and October 1989. EGF-R expression was determined by measuring the specific Bmax of125I EGF to tumor plasma membrane preparations. Tumor with a B max ≥ 3 fmol/mg of protein were considered positive with regard to EGF-R expression. With a median follow-up of 34 months, the 3-year overall and disease-free survivals are respectively 92% and 88% for EGF-R ≤ 3, and 91% and 86% EGF-R > 3 fmol, showing no significant difference, even when comparing axillary lymph node status. We did not succeed in finding an EGF-R cut-off value which might be significant in univariate analysis. Multivariate analysis of our data indicates that pT (p = 0.001), pN (p = 0.04), and Scarff-Bloom grade (p = 0.04) are the only significant predictors of disease-free survival among the parameters investigated in this study.

Key words

epidermal growth factor receptor breast cancer prognostic factor 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Benraad TJ, Foekens JA: Hydroxylapatite assay to measure epidermal growth factor receptor in human primary breast tumors. Ann Clin Biochem 27: 272–273, 1990Google Scholar
  2. 2.
    Bolla M, Chedin M, Souvignet C, Marron J, Arnould C, Chambaz EM: Estimation of epidermal growth factor receptor in 177 breast cancers. Correlation with prognostic factors. Breast Cancer Res Treat 16: 97–102, 1990Google Scholar
  3. 3.
    Bolla M, Chedin M, Colonna M, Marron J, Rostaing-Puissant B, Chambaz EM: Prognostic value of epidermal growth factor receptor in a series of 303 breast cancers. Eur J Cancer 28A: 1052–1054, 1992Google Scholar
  4. 4.
    Falette N, Lefebvre ML, Meggouh F, Eynard M, Garin E, Saez S: Measurement of epidermal growth factor occupied and non occupied receptor sites in 216 human breast cancer biopsies. Breast Cancer Res Treat 20: 177–183, 1991Google Scholar
  5. 5.
    Fitzpatrick SL, Brightwell J, Wittliff JL, Barrows GH, Schultz GS: Epidermal growth factor binding by breast tumor biopsies and relationship to oestrogen receptor and progestin receptor levels. Cancer Res 44: 3448–3453, 1984Google Scholar
  6. 6.
    Foekens JA, Portengen H, Van Putten WLJ, Trapman A, Reubi JC, Alexieva-Figusch J, Klijn JGM: Prognostic value of receptors for insuline-like growth factor 1, somatostatin and epidermal growth factor in human breast cancer. Cancer Res 49: 7002–7009, 1989Google Scholar
  7. 7.
    Formento JL, Francoual M, Formento P, Etienne MC, Fischel JL, Namer M, Frenay M, François E, Milano G: Epidermal growth factor receptor assay: validation of a single point method and application to breast cancer. Breast Cancer Treat Res 17: 211–219, 1990Google Scholar
  8. 8.
    Gasparini G, Bevilacqua P, Pozza F, Meli S, Boracchi P, Marubini E, Sainsbury JRC: Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br J Cancer 66: 970–976, 1992Google Scholar
  9. 9.
    Grimaux M, Romain S, Remvikos Y, Martin PM, Magdelenat H: Prognostic value of epidermal growth factor receptor in node positive breast cancer. Breast Cancer Res Treat 14: 77–90, 1989Google Scholar
  10. 10.
    Koenders PG, Beex LVAM, Geurts-Moespot A, Heuvel JJTM, Kienhuis CBM, Benraad TJ: Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor positive human primary breast cancers. Cancer Res 51: 4544–4548, 1991Google Scholar
  11. 11.
    Koenders P, Beex LVAM, Kienhuis C, Kloppenborg P, Benraad T: Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study. Breast Cancer Res Treat 23: abstract 16, 134, 1992Google Scholar
  12. 12.
    Nicholson S, Sainsbury JRC, Halcrow P, Kelly P, Angus B, Wright C, Henry Y, Farndon JR, Harris AL: Epidermal growth factor receptor: results of a six year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 63: 146–151, 1991Google Scholar
  13. 13.
    Osborne CK: Prognostic factors for breast cancer: have they met their promise? J Clin Oncol 10: 679–682, 1992Google Scholar
  14. 14.
    Rostaing-Puissant B, Chedin M, Chambaz EM, Bolla M: Activité protéine (Tyrosine)-kinases dans les tumeurs du sein. Relation avec les divers paramètres de pronostic. Bull Cancer 78: 482–483, 1991Google Scholar
  15. 15.
    Sainsbury JRC, Farndon JR, Sherbet GV, Harris AL: Epidermal growth factor receptors and estrogen receptors in human breast cancer. Lancet i: 364–366, 1985Google Scholar
  16. 16.
    Sainsbury JRC, Farndon JR, Needham GK, Malcom AJ, Harris AL: Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer. Lancet i: 1398–1402, 1987Google Scholar
  17. 17.
    Sokal R, Rohlt F (eds): Biometry. Freeman, New York, 1981Google Scholar
  18. 18.
    Spyratos F, Delarue JC, Andrieu C, Lidereau R, Champene MH, Hacène K, Brunet M: Epidermal growth factor receptors and prognosis in primary breast cancer. Breast Cancer Res Treat 17: 83–90, 1990Google Scholar
  19. 19.
    Toi M, Osaki A, Yamada H, Toge T: Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur J Cancer 27: 977–980, 1991Google Scholar

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • M. Bolla
    • 1
  • M. Chedin
    • 2
  • M. Colonna
    • 1
  • J. Marron-Charrière
    • 4
  • B. Rostaing-Puissant
    • 2
  • D. Pasquier
    • 3
  • M. H. Panh
    • 3
  • P. Winckel
    • 5
  • E. M. Chambaz
    • 2
  1. 1.Departments of RadiotherapyC.H.U.A. MichallonGrenoble Cedex 9France
  2. 2.BiochemistryC.H.U.A. MichallonGrenoble Cedex 9France
  3. 3.PathologyC.H.U.A. MichallonGrenoble Cedex 9France
  4. 4.Unité de ConcertationC.H.U.A. MichallonGrenoble Cedex 9France
  5. 5.Clinique du MailGrenobleFrance

Personalised recommendations